WH Smith Investigation, BBVA's Record Buyback, and Ipsen Drug Trial Failure | Stock Movers

WH Smith Faces FCA Investigation

• 📉 WH Smith shares have fallen over 6% following confirmation of an investigation by the UK's Financial Conduct Authority (FCA).
• 🔍 This probe stems from an accounting error in their North American business, which previously led to the CEO's resignation and a stock slump.
• 📊 Deloitte's findings highlighted a lack of oversight, contributing to the ongoing scrutiny.
• ⚠️ The company has also cut its dividend for the first time since the pandemic, and its stock is down over 40% year-to-date.
• ⚖️ Analysts suggest WH Smith's credibility is at stake, with close attention on the FCA's findings.

BBVA Announces Largest Ever Share Buyback

• 💰 BBVA SA is launching its largest-ever share buyback, valued at just under 4 billion euros, in two stages over approximately 12 months.
• 🚀 The first stage, worth 1.5 billion euros, begins Monday, with the overall buyback being a significant move to draw a line under its failed bid for Banco Sabadell.
• ✅ This large payout was largely anticipated by the market following the collapse of the Sabadell acquisition.
• 📈 Shares have seen a slight increase following the announcement.

Ipsen's Experimental Drug Trial Fails

• 💊 French pharmaceutical firm Ipsen saw its shares fall as an experimental oral drug for a rare bone disease failed to meet its primary endpoints in a five-year mid-stage trial.
• 💔 The study will now be closed, dashing hopes for developing this specific treatment.
• 💡 Bloomberg Intelligence notes this failure highlights Ipsen's need for Mergers and Acquisitions (M&A) to drive future growth, especially given competition.
• 📉 The drug trial setback is a significant disappointment for the company.